Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$1.34M$1.34M+7.7% vs Q1 2016 Net Income-$7.99M-$7.99MN/M vs Q1 2016 EPS Diluted-$0.19-$0.19N/M vs Q1 2016 Operating Income-$8,006,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived$25,592,000+1,206.6% Margins · derivedOperating margin-596.1%−244.7 pt vs Q1 2016
Net margin-595.2%−261.5 pt vs Q1 2016
ended Mar 31, 2017 · filed May 15, 2017 · 45 d after period end